Advertisement

Updated Analysis of the CANDOR Trial: Carfilzomib, Dexamethasone, and Daratumumab (KdD) vs Carfilzomib/Dexamethasone (Kd) in Relapsed or Refractory Multiple Myeloma
Posted: 12/16/2021 | By: Matthew Stenger

Question 1 of 5

In the updated analysis of the CANDOR trial, median follow-up was:

Choose 1

A
Approximately 17 months
B
Approximately 29 months
C
Approximately 27 months
D
Approximately 18 months

CategoriesView All Quizzes

Tumor Type


Additional Topics



Conference Coverage